- Optimizer
- Posts
- An Agonist Antagonist
An Agonist Antagonist
The Good, Bad, and Unknown Around Ozempic and The Rest
Table of Contents
In the early 1970’s Jens Juul Holst noticed something. The University of Copenhagen professor realized that directly following intestinal surgery, patients’ levels of insulin rose while blood sugar levels fell. Over time, he came to find that these changes were due to gut hormones like Glucagon — the “G” in GLP-1. I am not sure that there is anyone on earth more studied than Professor Holst so that’s where I started my journey of really understanding the pluses, minuses, past, present, and future of this class of drug. And where it will take the many adjacent industries that will change along with the worlds around them.
I am fascinated by Holst because he was so ahead of the curve, it makes me wonder how wide and tall the walls between science and industry are at times. How did it take so long post-discovery and post-study to hit the zeitgeist? GLP-1 was officially discovered in 1994, the below quote was written just five years later:
The gut hormone glucagon-like peptide 1 (GLP-1) has insulinotropic and anorectic effects during intravenous infusion and has been proposed as a new treatment for Type 2 Diabetes and obesity.
But that was just the beginning of my fascination with the GLP-1 class of drug responsible for the new jawlines and blousier clothes of our neighbors, favorite actors, politicians, media moguls, and indie fashion designers.
Reading Johann Hari's latest book, "Magic Pill" further sparked my curiosity and compelled me to write a deep dive into the world of injectable GLP-1 agonists, better known as Ozempic or Wegovy. Glucagon-like peptide-1 receptor agonists are a class of drugs that lower blood sugar levels and decrease energy intake by stimulating the GLP-1 receptor that curbs hunger.
There are unknown unknowns.
Hari's latest is a tapestry of scientific exploration, personal anecdotes, and societal critique that examines the extraordinary benefits and disturbing risks of these new weight loss drugs. Through his meticulous research and engaging storytelling, Hari presented a balanced view of the subject, inviting readers to understand the complexity of the issue without oversimplifying it.
Reply